Clinical Research Directory
Browse clinical research sites, groups, and studies.
Assessment of Drug-drug Interactions Between Feminizing Hormone Therapy and Emtricitabine/Tenofovir Alafenamide Concomitantly for Pre-exposure Prophylaxis Among Transgender Women
Sponsor: Thai Red Cross AIDS Research Centre
Summary
Recent studies have showed that there were significant drug-drug interactions (DDI) from feminizing hormone therapy (FHT) towards emtricitabine/tenofovir disoproxil fumarate (F/TDF)-based pre-exposure prophylaxis (PrEP) among transgender women (TGW). New strategies for PrEP among TGW who use FHT are urgently needed. Because tenofovir alafenamide (TAF) can achieve higher intracellular TFV-DP levels with lower tenofovir plasma concentrations, it is promising that both plasma TFV and intracellular TFV-DP levels might not be significantly affected by FHT. The current study aims to determine the pharmacokinetics DDI between FHT and F/TAF-based PrEP among TGW.
Official title: Institute of HIV Research and Innovation (IHRI)
Key Details
Gender
MALE
Age Range
18 Years - 40 Years
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2022-01-24
Completion Date
2025-10-01
Last Updated
2024-11-25
Healthy Volunteers
Yes
Conditions
Interventions
Estradiol valerate 2 mg, cyproterone acetate 25 mg
The entire study period will be approximately 1 year, which will include around 2 months of document preparation, 5 months of recruitment, 3 months of follow-up, and 2 months of data analysis.
Locations (1)
Institute of HIV Research and Innovation (IHRI)
Bangkok, Pathumwan, Thailand